Le Lézard
Classified in: Health, Covid-19 virus
Subject: PSF

Luna Vineyards Update to the COVID-19 Response


NAPA, Calif., March 30, 2020 /PRNewswire/ -- Luna Vineyards prides its ethical and business decisions to protect the wellbeing of its staff, customers and club members at all times. Out of an abundance of caution, Luna Vineyards decided to take decisive measures before the COVID-19 directive came through the Governor's Office of California this month.

"Without exception, doing what's best for Luna always means doing what is best for Luna's employees," says CEO Andre Crisp. Luna introduced an innovative way for Tasting Room staff to work from home. The Direct to Consumer Telesales Plan charts sales goals for the remainder of the quarter, managed by the Director of Guest Services James Foster. "With a mandatory shelter-in-place, our members have reached out asking how they can support Luna, and the best way is to continue buying and enjoying Luna Vineyards wines."

To ensure winemaking and cellar activities continue, winemaking personnel remain onsite observing CDC social distancing recommendations. Leadership, administrative, and enterprise sales personnel continue to work from their home offices. "Participation has to come from everyone. We are in this together and Luna staff are committed to maintaining each other's wellbeing, then turning the focus on collaborative ways among departments to find innovative alternatives and opportunities to engage our customers," says Andre Crisp.

The teams are working together to launch a series of live online tastings of its Estate and Reserve wines, pre-releases, and wine club favorites on Instagram, Facebook, and Zoom. "In a virtual space, the intimacy and transparency between our club members, guests, and the Chief Winemaker is a magical exchange," says Nisha Singh, VP of Marketing.

Luna Vineyards is launching a Spring Relief Initiative to help local healthcare providers and its workers who have dedicated their lives to serving our communities. During March and April, Luna Vineyards will donate a percentage of wine sales to OLE Health in Napa Valley, a community health center impacted by the COVID-19 Pandemic.

"During this unprecedented moment in our world, let's join together to support and inspire one another. Luna's visitor center may be empty and wine country quiet, but nothing will silence the collective resolve of Napa Valley," says Andre Crisp, CEO of Luna Vineyards

About Luna Vineyards:

Luna Vineyards' pioneering roots began at its estate in Napa Valley 25 years ago. Luna celebrates its innovative vision today under the leadership of winery President Andre Crisp and award-winning Chief Winemaker Shawna Miller. For more information, please visit www.lunavineyards.com.

Media Contact:
Nisha Singh
Email: [email protected]

Related Images

luna-vineyards.png
Luna Vineyards

SOURCE Luna Vineyards


These press releases may also interest you

at 22:03
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

at 22:00
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...



News published on and distributed by: